The Serum Tumor Associated Material (TAM) Detection For Chemotherapy Efficacy Prediction In Non-small Cell Lung Cancer

Objective:The characteristics of tumorigenesis and development are abnormal of glycolipids and glycoproteins. Tumor invasion or metastasis can affect the collagen, elastin and bone tissue, the composition of substances such as hydroxyproline metabolism disorder, resulting in elevated levels are found in the blood, these substances are collectively referred to as tumor-associated substances. The incidence of lung cancer increased year by year, and has become the leading cause of cancer death. Non-small cell lung cancer (NSCLC) accounts for more than85%of all lung cancer, however, no specific tumor markers were found to correlate with the development of NSCLC. Currently, several tumor markers that are clinically used for prediction of NSCLC include carcinoembryonic antigen (CEA), carbohydrate antigen125(CA125), carbohydrate antigen19-9(CA19-9) and so on.Serum tumor associated material (TAM) testing kit was a new test kit developed to detect serum tumor-associated substances,can be quickly and easily used for cancer early detection, screening, and monitoring the efficacy of cancer treatment. Its detection principle is that by the end of the sialic acid content, the end of the glycan epitopes and hydroxyproline content to detect the tumor. TAM currently reported for tumor screening, early diagnosis, differential diagnosis of benign and malignant tumors, but has not been reported for the prediction of NSCLC to chemotherapy. The aim of this study was to explore the associations of serum tumor associated material (TAM) with other common tumor markers like CEA, CA125and CA19-9and their chemotherapy efficacy prediction in NSCLC patients. Methods:All patients enrolled into this study were histologically or cytologically confirmed NSCLC. With the method of chemical colorimetry, the level of TAM was determined and compared, while chemiluminescence was used to measure the levels of common tumor markers. The blood sample was tested before and after each chemotherapy and every two cycles of chemotherapy. According to computed tomography(CT) or magnetic resonance imaging (MRI) before and after chemotherapy to evaluate efficacy by the Response Evaluation Criteria in of Solid Tumors (RECIST)Results:A total of87NSCLC patients were enrolled into this study. There were69cases of patients belonged to disease control (complete response+partial response+stable, CR+PR+SD),18cases belonged to disease progression (PD). The number of TAM decreased after chemotherapy for disease control was53, the sensitivity was76.8%; TAM increased in disease progression was10, the sensitivity was55.6%(Fisher’s exact test, P=0.018). TAM for the positive predictive value-the proportion of PD patients in TAM increased after chemotherapy was38.5%in PD patients and86.9%for the negative predictive value-the proportion of disease control patients in TAM decreased after chemotherapy in disease controlled patients. The efficacy evaluation compliance rate was72.4%which was defined as the ratio of the sum of disease progressors in the TAM increased and disease control in the TAM decreased of the all study cases.Conclusions:TAM detected malignant tumors through the detection of terminal sialic acid, the end of the polysaccharide antigen epitope and hydroxyproline. It had a higher sensitivity in the efficacy prediction of NSCLC chemotherapy, can be used as an indicator for efficacy prediction of NSCLC chemotherapy.